Wall Street Zen upgraded Gilead Sciences from hold to buy on Saturday. This rating change follows a U.S. appeals court ruling that upheld an injunction against importing the company's HIV medications from overseas.
The court decision protects Gilead's pricing structures and distribution channels from alternative funding programs. This ruling safeguards the company's sales and patient-assistance economics.
Separately, investment firm Abundance Wealth Counselors nearly doubled its stake in Gilead Sciences.